Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization

19971,897 citationsJournal Articlebronze Open Access

Authors

The EPILOG Investigators · Cleveland Clinic

Abstract

Inhibition of the platelet glycoprotein IIb/IIIa receptor with abciximab, together with low-dose, weight-adjusted heparin, markedly reduces the risk of acute ischemic complications in patients undergoing percutaneous coronary revascularization, without increasing the risk of hemorrhage.

Topics & Keywords

Acute Myocardial Infarction Research Heparin-Induced Thrombocytopenia and Thrombosis Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 336, Issue 24, pp. 1689-1697

DOI: 10.1056/nejm199706123362401

Field-Weighted Citation Impact: 128.40